Sophie E Willis

ORCID

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 5

Top Venues

The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society

British journal of cancer

Nature communications

Blood

AstraZeneca PLC

University of Leeds Faculty of Biological Sciences (BSC)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

AstraZeneca PLC May 01 2019

United Kingdom

Senior Scientist :: Early Stage Translational Pathology

AstraZeneca PLC Jul 04 2016 - Apr 30 2019

United Kingdom

Scientist

Education History

University of Leeds Faculty of Biological Sciences Sep 19 2012 - Jun 30 2016

United Kingdom

BSC

Publications

Elizabeth J Wiseman, Jennifer I Moss, James Atkinson, Hana Baakza, Emily Hayes, Sophie E Willis, Paul M Waring, Jaime Rodriguez Canales, Gemma N Jones
Epitope Lability of Phosphorylated Biomarkers of the DNA Damage Response Pathway Results in Increased Vulnerability to Effects of Delayed or Incomplete Formalin Fixation. The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society (2023)
Elizabeth J Wiseman, Jennifer I Moss, James Atkinson, Hana Baakza, Emily Hayes, Sophie E Willis, Paul M Waring, Jaime Rodriguez Canales, Gemma N Jones
Epitope Lability of Phosphorylated Biomarkers of the DNA Damage Response Pathway Results in Increased Vulnerability to Effects of Delayed or Incomplete Formalin Fixation. The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society (2023)
Sophie E Willis, Claudia Winkler, Martine P Roudier, Tarrion Baird, Paola Marco-Casanova, Emma V Jones, Philip Rowe, Jaime Rodriguez-Canales, Helen K Angell, Felicia S L Ng, Paul M Waring, Darren Hodgson, Jonathan A Ledermann, Johanne I Weberpals, Emma Dean, Elizabeth A Harrington, J Carl Barrett, Andrew J Pierce, Elisabetta Leo, Gemma N Jones
Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response. British journal of cancer 125 (12) (2021)
Antonio Sacco, Cinzia Federico, Katia Todoerti, Bachisio Ziccheddu, Valentina Palermo, Arianna Giacomini, Cosetta Ravelli, Federica Maccarinelli, Giada Bianchi, Angelo Belotti, Rossella Ribolla, Vanessa Katia Favasuli, Alexey S Revenko, A Robert Macleod, Brandon Willis, Hongbo Cai, Joana Hauser, Claire Rooney, Sophie E Willis, Philip Lloyd Martin, Anna D Staniszewska, Helen Ambrose, Lyndsey Hanson, Chiara Cattaneo, Alessandra Tucci, Giuseppe Rossi, Roberto Ronca, Antonino Neri, Stefania Mitola, Niccolò Bolli, Marco Presta, Michele Moschetta, Sarah Ross, Aldo M Roccaro
Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited antitumor activity. Blood 138 (18) (2021)
Jacqueline H L Fok, Antonio Ramos-Montoya, Mercedes Vazquez-Chantada, Paul W G Wijnhoven, Valeria Follia, Neil James, Paul M Farrington, Ankur Karmokar, Sophie E Willis, Jonathan Cairns, Jenni Nikkilä, David Beattie, Gillian M Lamont, M Raymond V Finlay, Joanne Wilson, Aaron Smith, Lenka Oplustil O'Connor, Stephanie Ling, Stephen E Fawell, Mark J O'Connor, Simon J Hollingsworth, Emma Dean, Frederick W Goldberg, Barry R Davies, Elaine B Cadogan
AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity. Nature communications 10 (1) (2019)

Sophie E Willis.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Sophie E Willis